Aerosolized amikacin and oral clarithromycin to eradicate Mycobacterium abscessus in a patient with cystic fibrosis: an 8-year follow-up.
Colin
Andrew A
AA
Ali-Dinar
Tarig
T
D000284:Administration, Oral; D000328:Adult; D000583:Amikacin / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D017291:Clarithromycin / Q000008:administration & dosage*; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000382:microbiology*; D004359:Drug Therapy, Combination; D005260:Female; D005541:Forced Expiratory Volume; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy; D006801:Humans; D009161:Mycobacterium / Q000187:drug effects*; D009164:Mycobacterium Infections / Q000188:drug therapy*; D009330:Nebulizers and Vaporizers; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification; D020615:Stenotrophomonas maltophilia / Q000187:drug effects
D000900:Anti-Bacterial Agents; D000583:Amikacin; D017291:Clarithromycin